Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
Nov 21 IONS Why Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?
Nov 20 ABBV Unpacking the Latest Options Trading Trends in AbbVie
Nov 20 VRTX Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Could Be 48% Below Their Intrinsic Value Estimate
Nov 20 IONS Ionis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right Now
Nov 19 VRTX Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)
Nov 19 ABBV Where Will AbbVie Be in 5 Years?
Nov 19 ABBV ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
Nov 19 ABBV RVPH: Year-End OLE Update
Nov 19 ABBV What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
Nov 18 ABBV AbbVie snaps eight straight sessions of losses
Nov 18 ABBV Aldeyra announces FDA acceptance of resubmitted reproxalap application
Nov 18 ABBV AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
Nov 18 IONS Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Nov 18 ABBV Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov 18 ABBV AbbVie’s Elahere wins European approval for certain ovarian cancers
Nov 18 ABBV Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Nov 18 ABBV AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
Nov 17 ABBV Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
Nov 17 VRTX Top 10 most expensive stocks (only 1 gets a Quant Sell)
Nov 17 ABBV AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags